Global Drugs for Malaria 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI01256854

Publication Date:

December 31, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Drugs for Malaria market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.
Anti-malarial Drugs are available only with a physician"s prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.
In the U.S. market, the major manufacturers are Cipla, Guilin Southern Medicine, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aentis and Ajanta Pharma, etc, with about 73% market shares.
The 鈥淒rugs for Malaria Industry Forecast鈥� looks at past sales and reviews total world Drugs for Malaria sales in 2024, providing a comprehensive analysis by region and market sector of projected Drugs for Malaria sales for 2025 through 2031. With Drugs for Malaria sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for Malaria industry.
This Insight Report provides a comprehensive analysis of the global Drugs for Malaria landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Drugs for Malaria portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Drugs for Malaria market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Malaria and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Malaria.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Malaria market by product type, application, key players and key regions and countries.
Segmentation by Type:
Aryl Aminoalcohol Compounds
Antifolate Compounds
Artemisinin Compounds
Segmentation by Application:
Prevention
Treatment
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Cipla
Guilin Pharmaceutical
IPCA Laboratories
GlaxoSmithKline
Mylan Labs
Roche
Novartis
Sanofi Aventis
Ajanta Pharma

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Drugs for Malaria 麻豆原创 Size (2020-2031)
2.1.2 Drugs for Malaria 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Drugs for Malaria by Country/Region (2020, 2024 & 2031)
2.2 Drugs for Malaria Segment by Type
2.2.1 Aryl Aminoalcohol Compounds
2.2.2 Antifolate Compounds
2.2.3 Artemisinin Compounds
2.3 Drugs for Malaria 麻豆原创 Size by Type
2.3.1 Drugs for Malaria 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Drugs for Malaria 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Drugs for Malaria Segment by Application
2.4.1 Prevention
2.4.2 Treatment
2.4.3 Others
2.5 Drugs for Malaria 麻豆原创 Size by Application
2.5.1 Drugs for Malaria 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Drugs for Malaria 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Drugs for Malaria 麻豆原创 Size by Player
3.1 Drugs for Malaria 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Drugs for Malaria Revenue by Player (2020-2025)
3.1.2 Global Drugs for Malaria Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Drugs for Malaria Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Drugs for Malaria by Region
4.1 Drugs for Malaria 麻豆原创 Size by Region (2020-2025)
4.2 Global Drugs for Malaria Annual Revenue by Country/Region (2020-2025)
4.3 Americas Drugs for Malaria 麻豆原创 Size Growth (2020-2025)
4.4 APAC Drugs for Malaria 麻豆原创 Size Growth (2020-2025)
4.5 Europe Drugs for Malaria 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Drugs for Malaria 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Drugs for Malaria 麻豆原创 Size by Country (2020-2025)
5.2 Americas Drugs for Malaria 麻豆原创 Size by Type (2020-2025)
5.3 Americas Drugs for Malaria 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drugs for Malaria 麻豆原创 Size by Region (2020-2025)
6.2 APAC Drugs for Malaria 麻豆原创 Size by Type (2020-2025)
6.3 APAC Drugs for Malaria 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Drugs for Malaria 麻豆原创 Size by Country (2020-2025)
7.2 Europe Drugs for Malaria 麻豆原创 Size by Type (2020-2025)
7.3 Europe Drugs for Malaria 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Drugs for Malaria by Region (2020-2025)
8.2 Middle East & Africa Drugs for Malaria 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Drugs for Malaria 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Drugs for Malaria 麻豆原创 Forecast
10.1 Global Drugs for Malaria Forecast by Region (2026-2031)
10.1.1 Global Drugs for Malaria Forecast by Region (2026-2031)
10.1.2 Americas Drugs for Malaria Forecast
10.1.3 APAC Drugs for Malaria Forecast
10.1.4 Europe Drugs for Malaria Forecast
10.1.5 Middle East & Africa Drugs for Malaria Forecast
10.2 Americas Drugs for Malaria Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Drugs for Malaria Forecast
10.2.2 Canada 麻豆原创 Drugs for Malaria Forecast
10.2.3 Mexico 麻豆原创 Drugs for Malaria Forecast
10.2.4 Brazil 麻豆原创 Drugs for Malaria Forecast
10.3 APAC Drugs for Malaria Forecast by Region (2026-2031)
10.3.1 China Drugs for Malaria 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Drugs for Malaria Forecast
10.3.3 Korea 麻豆原创 Drugs for Malaria Forecast
10.3.4 Southeast Asia 麻豆原创 Drugs for Malaria Forecast
10.3.5 India 麻豆原创 Drugs for Malaria Forecast
10.3.6 Australia 麻豆原创 Drugs for Malaria Forecast
10.4 Europe Drugs for Malaria Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Drugs for Malaria Forecast
10.4.2 France 麻豆原创 Drugs for Malaria Forecast
10.4.3 UK 麻豆原创 Drugs for Malaria Forecast
10.4.4 Italy 麻豆原创 Drugs for Malaria Forecast
10.4.5 Russia 麻豆原创 Drugs for Malaria Forecast
10.5 Middle East & Africa Drugs for Malaria Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Drugs for Malaria Forecast
10.5.2 South Africa 麻豆原创 Drugs for Malaria Forecast
10.5.3 Israel 麻豆原创 Drugs for Malaria Forecast
10.5.4 Turkey 麻豆原创 Drugs for Malaria Forecast
10.6 Global Drugs for Malaria Forecast by Type (2026-2031)
10.7 Global Drugs for Malaria Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Drugs for Malaria Forecast
11 Key Players Analysis
11.1 Cipla
11.1.1 Cipla Company Information
11.1.2 Cipla Drugs for Malaria Product Offered
11.1.3 Cipla Drugs for Malaria Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Cipla Main Business Overview
11.1.5 Cipla Latest Developments
11.2 Guilin Pharmaceutical
11.2.1 Guilin Pharmaceutical Company Information
11.2.2 Guilin Pharmaceutical Drugs for Malaria Product Offered
11.2.3 Guilin Pharmaceutical Drugs for Malaria Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Guilin Pharmaceutical Main Business Overview
11.2.5 Guilin Pharmaceutical Latest Developments
11.3 IPCA Laboratories
11.3.1 IPCA Laboratories Company Information
11.3.2 IPCA Laboratories Drugs for Malaria Product Offered
11.3.3 IPCA Laboratories Drugs for Malaria Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 IPCA Laboratories Main Business Overview
11.3.5 IPCA Laboratories Latest Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Information
11.4.2 GlaxoSmithKline Drugs for Malaria Product Offered
11.4.3 GlaxoSmithKline Drugs for Malaria Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 GlaxoSmithKline Main Business Overview
11.4.5 GlaxoSmithKline Latest Developments
11.5 Mylan Labs
11.5.1 Mylan Labs Company Information
11.5.2 Mylan Labs Drugs for Malaria Product Offered
11.5.3 Mylan Labs Drugs for Malaria Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Mylan Labs Main Business Overview
11.5.5 Mylan Labs Latest Developments
11.6 Roche
11.6.1 Roche Company Information
11.6.2 Roche Drugs for Malaria Product Offered
11.6.3 Roche Drugs for Malaria Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Roche Main Business Overview
11.6.5 Roche Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Drugs for Malaria Product Offered
11.7.3 Novartis Drugs for Malaria Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 Sanofi Aventis
11.8.1 Sanofi Aventis Company Information
11.8.2 Sanofi Aventis Drugs for Malaria Product Offered
11.8.3 Sanofi Aventis Drugs for Malaria Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Sanofi Aventis Main Business Overview
11.8.5 Sanofi Aventis Latest Developments
11.9 Ajanta Pharma
11.9.1 Ajanta Pharma Company Information
11.9.2 Ajanta Pharma Drugs for Malaria Product Offered
11.9.3 Ajanta Pharma Drugs for Malaria Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Ajanta Pharma Main Business Overview
11.9.5 Ajanta Pharma Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.